Fresenius Medical Care AG
FME: XETR (DEU)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $gz | LOCK|QK<K | LOCK|WVk<qvZ |
Fresenius Medical Care: Flat 2026 Outlook Underwhelms After Very Strong End to 2025
In the fourth quarter, Fresenius delivered growth of 8% in organic revenue, 53% in adjusted operating income, and 68% in adjusted EPS. Including headwinds like investments in a new product launch, it issued guidance for roughly stable 2026 operating profits. Shares fell about 3% in early trading.
